Current and prospective treatment options for Sjögren’s syndrome

References

• Moutsopoulos HM, Tzioufas AG. Sjögren’s syndrome. In: Rheumatology (2nd Edition). Klippel JH, Dieppe PA (Eds). Mosby, St Louis, MO, USA 27, 1–12 (1994).
   Google Scholar
• Fox RI. Sjogren’s syndrome [review]. Lancet366, 321–331 (2005).
   PubMed Web of Science ®Google Scholar
• Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren’s syndrome. Arthritis Rheum.46, 741–747 (2002).
   PubMed Web of Science ®Google Scholar
• Dong L, Masaki Y, Takegami, T et al. Clonality analysis of lymphoproliferative disorders in patients with Sjogren’s syndrome. Clin. Exp. Immunol.150, 279–284 (2007).
   Google Scholar
• Masaki Y, Sugai S. Lymphoproliferative disorders in Sjögren’s syndrome. Autoimmun. Rev.3(3), 175–182 (2004).
   PubMed Web of Science ®Google Scholar
• Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM. Malignant lymphoma in primary Sjogren’s syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren’s Syndrome. Arthritis Rheum.42, 1765–1772 (1999).
   PubMed Web of Science ®Google Scholar
• Cui G, Sugai S, Ogawa Y, Takeshita S, Masaki Y, Fukutoku M. [Long-term follow-up of 43 patients with Sjögren’s syndrome]. Ryumachi37(6), 770–780 (1997).
   Google Scholar
• Skopouli FN, Dafni U, loannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjögren’s syndrome. Semin. Arthritis Rheum.29, 296–304 (2000).
   PubMed Web of Science ®Google Scholar
• Vivino FB, Al-Hashimi I, Khan Z et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-0I Study Group. Arch. Intern. Med.159, 174–181 (1999).
   PubMed Web of Science ®Google Scholar
• Petrone D, Condemi JJ, Fife R, Gluck O, Cohen S, Dalgin P. A double-blind, randomized, placebo-controlled study of cevimeline in Sjogren’s syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum.46, 748–754 (2002).
   PubMed Web of Science ®Google Scholar
• Pijpe J, van Imhoff GW, Spijkervet FK et al. Rituximab treatment in patients with primary Sjogren’s syndrome: an open-label Phase II study. Arthritis Rheum.52, 2740–2750 (2005).
   PubMed Web of Science ®Google Scholar
• Nakamura H, Kawakami A, Eguchi K. Mechanisms of autoantibody production and the relationship between autoantibodies and the clinical manifestations in Sjogren’s syndrome. Transl. Res.148(6), 281–288 (2006).
   PubMed Web of Science ®Google Scholar
• Salomonsson S, Jonsson MV, Skarstein K et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogren’s syndrome. Arthritis Rheum.48, 3187–3201 (2003).
   PubMed Web of Science ®Google Scholar
• Pers JO, Devauchelle V, Daridon C et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren’s syndrome. Arthritis Rheum.56, 1464–1477 (2007).
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zeron P. New approaches in Sjögren’s syndrome therapy. Expert Rev. Clin. Immunol.3, 195–204 (2007).
   PubMedGoogle Scholar
• Thanou-Stavraki A, James JA. Primary Sjogren’s Syndrome. Current and prospective therapies. Semin. Arthtitis Rheum.37(5), 273–292 (2008).
   Google Scholar
• Cohen EJ. Punctal occlusion. Arch. Ophthalmol.117, 389–390 (1999).
   Google Scholar
• Noble BA, Loh RS, MacLennan S et al. Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease. Br. J. Ophthalmol.88, 647–652 (2004).
   PubMed Web of Science ®Google Scholar
• Geerling G, Maclennan S, Hartwig D. Autologous serum eye drops for ocular surface disorders. Br. J. Ophthalmol.88, 1467–1474 (2004).
   PubMed Web of Science ®Google Scholar
• Liu L, Hartwig D, Harloff S et al. Corneal epitheliotrophic capacity of three different blood-derived preparations. Invest. Ophthalmol. Vis. Sci.47, 2438–2444 (2006).
   PubMed Web of Science ®Google Scholar
• Sail K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmol.107, 631–639 (2000).
   Web of Science ®Google Scholar
• Kunert KS, Tisdale AS, Stern ME, Smith JA, Gipson IK. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch. Ophthalmol.118, 1489–1496 (2000).
   PubMed Web of Science ®Google Scholar
• Tsubota K, Fujita H, Tadano K et al. Improvement of lacrimal function by topical application of CyA in murine models of Sjogren’s syndrome. Invest. Ophthalmol. Vis. Sci.42, 101–110 (2001).
   PubMed Web of Science ®Google Scholar
• Strong B, Farley W, Stern ME, Pflugfelder SC. Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca Cornea24, 80–85 (2005).
   PubMed Web of Science ®Google Scholar
• Taylor P. Cholinergic agonists. In: Goodman and Gilman’s: The Pharmacologic Basis of Therapeutics (8th Edition). Gilman AG, Rail TW, Nies AS, Taylor P (Eds). Pergamon Press Inc., NY, USA 122–130 (1990).
   Google Scholar
• Tsifetaki N, Kitsos G, Paschides CA et al. Oral pilocarpine for the treatment of ocular symptoms in patients with Sjogren’s syndrome: a randomised 12 week controlled study. Ann. Rheum. Dis.62, 1204–1207 (2003).
   PubMed Web of Science ®Google Scholar
• Aragona P, Di Pietro R, Spinella R, Mobrici M. Conjunctival epithelium improvement after systemic pilocarpine in patients with Sjogren’s syndrome. Br. J. Ophthalmol.90, 166–170 (2006).
   PubMed Web of Science ®Google Scholar
• Ono M, Takamura E, Sliinozaki K et al. Therapeutic effect of cevimeline on dry eye in patients with Sjogren’s syndrome: a randomized, double-blind clinical study. Am. J. Ophthalmol.138, 6–17 (2004).
   PubMed Web of Science ®Google Scholar
• Urashima H, Okamoto T, Takeji Y, Shinohara H, Fujisawa S. Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated in vivo model. Cornea23(6), 613–619 (2004).
   PubMed Web of Science ®Google Scholar
• Nakamura M, Endo K, Nakata K, Hamano T. Gefarnate increases PAS positive cell density in rabbit conjunctiva. Br. J. Ophthalmol.82(11), 1320–1323 (1998).
   Google Scholar
• Toshida H, Nakata K, Hamano T, Nakamura M, Nguyen D, Beuerman RW. Effect of gefarnate on the ocular surface in squirrel monkeys. Cornea21(3), 292–299 (2002).
   PubMedGoogle Scholar
• Fife RS, Chase WF, Dore RK et al. Cevimeline for the treatment of xerostomia in patients with Sjogren syndrome: a randomized trial. Arch. Intern. Med.162, 1293–1300 (2002).
   PubMedGoogle Scholar
• Rosas J, Ramos-Casals M, Ena J et al. Usefulness of basal and pilocarpine-stimulated salivary flow in primary Sjogren’s syndrome. Correlation with clinical, immunological and histological features. Rheumatology (Oxford)41, 670–675 (2002).
   PubMed Web of Science ®Google Scholar
• Yamada H, Nakagawa Y, Wakamatsu E et al. Efficacy prediction of cevimeline in patients with Sjogren’s syndrome. Clin. Rheumatol.26(8), 1320–1327 (2007).
   PubMed Web of Science ®Google Scholar
• Hadden WB. On ‘dry mouth’ or suppression of the salivary and buccal secretions. Trans. Clin. Soc. London Bd.21(Suppl. 176), (1888).
   Google Scholar
• Brown JH, Taylor P. Muscarinic receptor agonists and antagonists. In: Goodman and Gilman’s the Pharmacologic Basis of Therapeutics (10th Edition). Hardman JG, Limbird LE, Goodman Gilman A (Eds). McGraw-Hill, NY, USA 155–173 (2001).
   Google Scholar
• Johnson JT, Ferretti GA, Nethery WJ et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N. Engl. J. Med.329, 390–395 (1993).
   PubMed Web of Science ®Google Scholar
• Sugai S, Koike T, Miyasaka N, Fujibayashi T, Konno A, Origasa H. [Dose-finding study of oral pilocarpine for the treatment of xerostomia associated with Sjögren’s syndrome]. Jpn. Pharmacol. Ther.35(Suppl.), S141–S153 (2007).
   Google Scholar
• Sugai S, Miyasaka N, Koike T, Origasa H, Sumida T, Kawai S. [Long-term study of oral pilocarpine for the treatment of xerostomia associated with Sjögren’s syndrome]. Jpn. Pharmacol. Ther.35(Suppl.) S155–S167 (2007).
   Google Scholar
• Bernardi R, Perin C, Becker FL et al. Effect of pilocarpine mouthwash on salivary flow. Braz. J. Med. Biol. Res.35(1), 105–110 (2002).
   Google Scholar
• Gibson J, Halliday JA, Ewert K, Robertson S. A controlled release pilocarpine buccal insert in the treatment of Sjögren’s syndrome. Br. Dent. J.202(7), E17, 404–405 (2007).
   Google Scholar
• Ohtani Y. [The Phase I study on FKS-508- single and a series dosage]. Rinnsho Iyaku6, 1551–1576 (1990).
   Google Scholar
• Iwabuchi Y, Masuhara T. Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: identification of a potential therapeutic agent for treatment of Sjögren’s syndrome. Gen. Pharmac.25, 123–129 (1994).
   PubMedGoogle Scholar
• Suzuki K, Matsumoto M, Nakashima M et al. Effect of cevimeline on salivary components in patients with Sjogren syndrome. Pharmacology74, 100–105 (2005).
   PubMed Web of Science ®Google Scholar
• Takagi Y, Kimura Y, Nakamura T. Cevimeline gargle for the treatment of xerostomia in patients with Sjogren’s syndrome. Ann. Rheum. Dis.63, 749 (2004).
   PubMed Web of Science ®Google Scholar
• Witherspoon LR. The interferons – clinical applications and new technologies. J. Nucl. Med.25, 817–821 (1984).
   Google Scholar
• Cummins JM, Beilharz MW, Krakowka S. Oral use of interferon. J. Interferon Cytokine Res.19, 853–857 (1999).
   Google Scholar
• Shiozawa S, Kuroki Y, Yoshihara R et al. Increasing effect of oral interferon-α in saliva secretion of Sjogren’s syndrome patients. Annual Meeting of the Japan Rheumatology Association, Nagoya, Japan, May 22–24, 1993. Abstract W-12–10.
   Google Scholar
• Shiozawa S, Tanaka Y, Shiozawa K. Single-blinded controlled trial of low-dose oral IFN-α for the treatment of xerostomia in patients with Sjogren’s syndrome. J. Interferon Cytokine Res.18, 255–262 (1998).
   PubMed Web of Science ®Google Scholar
• Ship JA, Fox PC, Michalek JE, Cummins MJ, Richards AB. Treatment of primary Sjogren’s syndrome with low-dose natural human interferon-α administered by the oromucosal route: a Phase II clinical trial. IFN Protocol Study Group. J. Interferon Cytokine Res.19, 943–951 (1999).
   PubMed Web of Science ®Google Scholar
• Cummins JM, Papas A, Kammer GM, Fox PC. Treatment of primary Sjögren’s syndrome with low-dose human interferon-α administered by the oromucosal route: combined Phase III results. Arthritis Rheum.49, 585–593 (2003).
   PubMed Web of Science ®Google Scholar
• Smith JK, Siddiqui AA, Modica LA et al. interferon-α upregulates gene expression of aquaporin-5 in human parotid glands. J. Interferon Cytokine Res.19(8), 929–935 (1999).
   PubMed Web of Science ®Google Scholar
• Arakawa T, Higuchi K, Fujiwara Y et al. 5th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig. Dis. Sci.50(Suppl. 1), S3–S11 (2005).
   PubMed Web of Science ®Google Scholar
• Bamba H, Ota S, Kato A et al. Effect of rebamipide on prostaglandin receptors-mediated increase of inflammatory cytokine production by macrophages. Aliment. Pharmacol. Ther.18(Suppl. 1), 113–118 (2003).
   Google Scholar
• Kohashi M, Ishimaru N, Arakaki R, Hayashi Y. Effective treatment of a mouse model of Sjögren’s syndrome with oral administration of rebamipide. Arthritis Rheum.58(2), 389–400 (2008).
   PubMed Web of Science ®Google Scholar
• Sugai S, Konda S, Shirasaki Y, Murayama T, Nishikawa T. Non-IgM monoclonal gammopathy in patients with Sjögren’s syndrome. Am. J. Med.68, 861–866 (1980).
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Anaya JM, García-Carrasco M et al. Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients. Medicine (Baltimore)83, 96–106 (2004).
   PubMed Web of Science ®Google Scholar
• Ferri C, Mascia MT. Cryoglobulinemic vasculitis. Curr. Opin. Rheumatol.18, 54–63 (2006).
   PubMed Web of Science ®Google Scholar
• Zaja F, De Vita S, Mazzaro C et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood101, 3827–3834 (2003).
   PubMed Web of Science ®Google Scholar
• Voulgarelis M, Giannouli S, Tzioufas AG, Moutsopoulos HM. Long term remission of Sjögren’s syndrome associated aggressive B cell non-Hodgkin’s lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann. Rheum. Dis.65, 1033–1037 (2006).
   PubMed Web of Science ®Google Scholar
• Ansell SM, Armitage J. Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin. Proc.80, 1087–1097 (2005).
   PubMed Web of Science ®Google Scholar
• Miyawaki S, Nishiyama S, Matoba K. Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjogren’s syndrome. Intern. Med.38, 938–943 (1999).
   PubMed Web of Science ®Google Scholar
• Zandbelt MM, van den Hoogen FH, de Wilde PC, van den Berg PJ, Schneider HG, van de Putte LB. Reversibility of histological and immunohistological abnormalities in sublabial salivary gland biopsy specimens following treatment with corticosteroids in Sjogren’s syndrome. Ann. Rheum. Dis.60, 511–513 (2001).
   PubMed Web of Science ®Google Scholar
• Izumi M, Eguchi K, Nakamura H, Takagi Y, Kawabe Y, Nakamura T. Corticosteroid irrigation of parotid gland for treatment of xerostomia in patients with Sjogren’s syndrome. Ann. Rheum. Dis.57, 464–469 (1998).
   PubMed Web of Science ®Google Scholar
• Fox RI, Chan E, Benton L, Fong S, Friedlaender M, Howell FV. Treatment of primary Sjogren’s syndrome with hydroxychloroquine. Am. J. Med.85, 62–67 (1988).
   PubMed Web of Science ®Google Scholar
• Tishler M, Yaron I, Shirazi I, Yaron M. Hydroxychloroquine treatment for primary Sjögren’s syndrome: its effect on salivary and serum inflammatory markers. Ann. Rheum. Dis.58, 253–256 (1999).
   PubMed Web of Science ®Google Scholar
• Hirohata S, Nakanishi K, Yanagida T. Inhibition of cyclin A gene expression in human B cells by an immunosuppressant mizoribine. Clin. Exp. Immunol.120, 448–453 (2000).
   Google Scholar
• Kamada H, Itoh H, Shibata H, Koshio T, Hayashi A, Nakagami K. Inhibitory mechanism of mizoribine on the antibody production of mouse B cells stimulated with lipopolysaccharide. Jpn. J. Pharmacol.74, 323–330 (1997).
   Google Scholar
• Mizuno K, Tsujino M, Takada M, Hayashi M, Atsumi K, Matsuda T. Studies on bredinin. I. Isolation, characterization and biological properties. J. Antibiot. (Tokyo)27, 775–784 (1974).
   PubMed Web of Science ®Google Scholar
• Nakayamada S, Saito K, Nakatsuka K et al. Efficacy of mizoribine treatment in patients with Sjogren’s syndrome: an open pilot trial. Mod. Rheumatol.13, 339–345 (2003).
   PubMedGoogle Scholar
• Nakayamada S, Saito K, Umehara H et al. Efficacy and safety of mizoribine for treatment of Sjögren’s syndrome: a multicenter open-label clinical trial. Mod. Rheumatol.17(6), 464–469 (2007).
   PubMed Web of Science ®Google Scholar
• Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo A. A 39 kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc. Natl Acad. Sci. USA89, 6550–6554 (1992).
   PubMed Web of Science ®Google Scholar
• Hollenbaugh D, Grosmaire LS, Kullas CD et al. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J.11(12), 4313–4321 (1992).
   PubMed Web of Science ®Google Scholar
• Van den Eertwegh AJ, Noelle RJ, Roy M et al.in vivo CD40–gp39 interactions are essential for thymus-dependent humoral immunity. I. in vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T–B cell interactions. J. Exp. Med.178, 1555–1565 (1993).
   PubMed Web of Science ®Google Scholar
• Gray D, Siepmann K, Wohlleben G. CD40 ligation in B cell activation, isotype switching and memory development. Semin. Immunol.6, 303–310 (1994).
   PubMedGoogle Scholar
• Kessler HS. A laboratory model for Sjogren’s syndrome. Am. J. Pathol.52, 671–685 (1968).
   PubMed Web of Science ®Google Scholar
• Cui G, Sugai S. [Suppression of autoimmune diseases by blockade of the CD40-CD40L interaction]. J. Kanazawa Med. Univ.24, 137–144 (1999).
   Google Scholar
• Mariette X, Ravaud P, Steinfeld S et al. Inefficacy of infliximab in primary Sjogren’s syndrome: results of the randomized, controlled trial of remicade in primary Sjogren’s syndrome (TRIPSS). Arthritis Rheum.50, 1270–1276 (2004).
   PubMed Web of Science ®Google Scholar
• Zandbelt MM, de Wilde P, van Damme P, Hoyng CB, van de Putte L, van den Hoogen F. Etanercept in the treatment of patients with primary Sjogren’s syndrome: a pilot study. J. Rheumatol.31, 96–101 (2004).
   PubMed Web of Science ®Google Scholar
• Sankar V, Brennan MT, Kok MR et al. Etanercept in Sjogren’s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum.50, 2240–2245 (2004).
   PubMed Web of Science ®Google Scholar
• Devauchelle-Pensec V, Pennec Y, Morvan J et al. Improvement of Sjögren’s syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum.57, 310–317 (2007).
   PubMed Web of Science ®Google Scholar
• Looney RJ. Will targeting B cells be the answer for Sjogren’s syndrome? Arthritis Rheum.56(5), 1371–1377 (2007).
   Google Scholar
• Isaacson PG. Update on MALT lymphoma. Best Pract. Res. Clin. Haematol.18(1), 57–68 (2005).
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Sakaguchi N, Shimizu J et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev.182(8), 18–32 (2001).
   PubMed Web of Science ®Google Scholar
• Li X, Li X, Qian L et al. T regulatory cells are markedly diminished in diseased salivary glands of patients with primary Sjögren’s syndrome. J. Rheumatol.34(12), 2438–2445 (2007).
   PubMed Web of Science ®Google Scholar
• Kok MR, Yamano S, Lodde BM et al. Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjögren’s syndrome. Hum. Gene Ther.20, 1605–1618 (2003).
   Google Scholar
• Shan Z, Li J, Zheng C et al. Increased fluid secretion after adenoviral-mediated transfer of the human aquaporin-1 cDNA to irradiated miniature pig parotid glands. Mol. Ther.11(3), 444–451 (2005).
   PubMed Web of Science ®Google Scholar